FOX Translator
No data currently available.
No data currently available.
In the wide and varied family of the thousands and thousands of funds out there, the exchange-traded fund is one of the more consumer-friendly ones.
Unlike mutual funds, exchange-traded funds, or ETFs, behave more like stocks. You can buy
into an ETF at any time, and sell it whenever you feel like it. And like a stock, an ETF's value can rise and fall--depending
on what the ETF is invested in.What do ETFs invest in? Well, they're typically linked to an index like the Dow Jones Industrial
Average or the S&P 500. So, if you had an ETF that trades the same companies that make up the Dow or the S&P, it will
rise and fall in value pretty much the same amount as the Dow or S&P.
You can also buy ETFs that invest in other
types of products, like bonds, currencies, gold or other commodities. The ETF market has grown considerably in the past few
years, so there is no shortage of ETFs to invest in.
Home / Markets / Industries / Health Care
Friday, September 05, 2008
IntelGenx Corp. Welcomes New Chief Financial Officer, Paul Simmons
Comtex
SAINT LAURENT, QUEBEC, Sep 05, 2008 (MARKET WIRE via COMTEX) ----IntelGenx Technologies Corp. (TSX: IGX)(OTCBB: IGXT)("IntelGenx") - Management of IntelGenx welcomes Paul Simmons as Chief Financial Officer, effective September 1, 2008. A financial executive with more than 20 years of delivering fiscal gains and corporate growth worldwide, his expertise is in assisting international corporations to improved profitability. Paul has held CFO and VP-Finance positions with several manufacturers in agricultural machinery, hearing aids, and classic English knitwear.
"We welcome Paul to the IntelGenx Executive team and Canada. His international background in corporate finance, business expansion, mergers and acquisitions, process optimization and strategic alliances will be a significant contribution as we take this company to the next stages of success," said IntelGenx President and CEO, Dr. Horst G. Zerbe.
Added Paul Simmons, "This is an extremely exciting time to join IntelGenx, as it makes the significant move from pure R&D operation to delivering product - our first launch is scheduled for Q4 2008. I look forward to playing a part in strengthening the company's financial position, and contributing to corporate development and strategies."
About Paul Simmons
Paul brings significant international credentials to the finance function with an Association of Financial Controllers and Administration (AFCA) certification and a designation with the Association of Accounting Technicians (MAAT). He is well versed in U.S. Generally Accepted Accounting Principles (GAAP) and International Financial Reporting Standards (IFRS).
He has led the transformation from one application to the other in several organizations based on the commercial activities and best practices required for the company in the country of operation. Most recently he was employed within the CLAAS Group (2003 - 08), initially based at Group HQ in Germany as Head of Corporate Controlling until August 2005, and then seconded to the baler manufacturing subsidiary (Usines CLAAS France) where he implemented a successful turnaround - following many years of continuous losses. In September 2006 Paul was seconded to French subsidiary Renault Agriculture to restructure and integrate the newly acquired Tractor Manufacturing Division into the CLAAS Group.
About IntelGenx Corp.
IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of pain, hypertension, osteoarthritis, and depressive disorders. More information is available about the company at www.intelgenx.com.
This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
The TSX and OTCBB have neither approved nor disapproved of the information contained herein.
Contacts: IntelGenx Corp. Dr. Horst G. Zerbe President and CEO (514) 331-7440x201 Email: horst@IntelGenx.com Website: www.intelgenx.com
SOURCE: IntelGenx Corp.
mailto:horst@IntelGenx.com http://www.intelgenx.com
Copyright 2008 Market Wire, All rights reserved.
Market Snapshot
| Symbol | Last Price | Netchange | Volume |
|---|---|---|---|
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
